{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:12Z","timestamp":1792787292089,"version":"4.5.0"},"reference-count":33,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T00:00:00Z","timestamp":1641340800000},"content-version":"unspecified","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"SOTIO a.s."}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,11,26]]},"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Most patients with epithelial ovarian cancer (EOC) relapse despite primary debulking surgery and chemotherapy (CT). Autologous dendritic cell immunotherapy (DCVAC) can present tumor antigens to elicit a durable immune response. We hypothesized that adding parallel or sequential DCVAC to CT stimulates antitumor immunity and improves clinical outcomes in patients with EOC. Based on the interim results of sequential DCVAC\/OvCa administration and to accommodate the increased interest in maintenance treatment in EOC, the trial was amended by adding Part 2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with International Federation of Gynecology and Obstetrics stage III EOC (serous, endometrioid, or mucinous), who underwent cytoreductive surgery up to 3 weeks prior to randomization and were scheduled for first-line platinum-based CT were eligible. Patients, stratified by tumor residuum (0 or &lt;1\u2009cm), were randomized (1:1:1) to DCVAC\/OvCa parallel to CT (Group A), DCVAC\/OvCa sequential to CT (Group B), or CT alone (Group C) in Part 1, and to Groups B and C in Part 2. Autologous dendritic cells for DCVAC were differentiated from patients\u2019 CD14\n                      <jats:sup>+<\/jats:sup>\n                      monocytes, pulsed with two allogenic OvCa cell lines (SK-OV-3, OV-90), and matured in the presence of polyinosinic:polycytidylic acid. We report the safety outcomes (safety analysis set, Parts 1 and 2 combined) along with the primary (progression-free survival (PFS)) and secondary (overall survival (OS)) efficacy endpoints. Efficacy endpoints were assessed in the modified intention-to-treat (mITT) analysis set in Part 1.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between November 2013 and March 2016, 99 patients were randomized. The mITT (Part 1) comprised 31, 29, and 30 patients in Groups A, B, and C, respectively. Baseline characteristics and DCVAC\/OvCa exposure were comparable across the treatment arms. DCVAC\/OvCa showed a good safety profile with treatment-emergent adverse events related to DCVAC\/OvCa in 2 of 34 patients (5.9%) in Group A and 2 of 53 patients (3.8%) in Group B. Median PFS was 20.3, not reached, and 21.4 months in Groups A, B, and C, respectively. The HR (95% CI) for Group A versus Group C was 0.98 (0.48 to 2.00; p=0.9483) and the HR for Group B versus Group C was 0.39 (0.16 to 0.96; p=0.0336). This was accompanied by a non-significant trend of improved OS in Groups A and B. Median OS was not reached in any group after a median follow-up of 66 months (34% of events).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>DCVAC\/OvCa and leukapheresis was not associated with significant safety concerns in this trial. DCVAC\/OvCa sequential to CT was associated with a statistically significant improvement in PFS in patients undergoing first-line treatment of EOC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02107937\">NCT02107937<\/jats:ext-link>\n                      , EudraCT2010-021462-30.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2021-003190","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T11:42:21Z","timestamp":1641469341000},"page":"e003190","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":52,"title":["Safety and efficacy of dendritic cell-based immunotherapy DCVAC\/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct02107937","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Lukas","family":"Rob","sequence":"first","affiliation":[{"name":"Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6387-9356","authenticated-orcid":false,"given":"David","family":"Cibula","sequence":"additional","affiliation":[{"name":"First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Knapp","sequence":"additional","affiliation":[{"name":"Department of Gynaecologic Oncology, Medical University of Bialystok, Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mallmann","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslav","family":"Klat","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, University Hospital Ostrava and University of Ostrava, Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubos","family":"Minar","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, University Hospital Brno and Masaryk University, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Bartos","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Hospital Novy Jicin Novy Jicin, Novy Jicin, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Chovanec","sequence":"additional","affiliation":[{"name":"Masaryk Memorial Cancer Institute, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Valha","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Hospital Ceske Budejovice, \u010cesk\u00e9 Bud\u011bjovice, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Pluta","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, 2nd Faculty of Medicine, University Hospital Motol, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdenek","family":"Novotny","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Faculty Hospital Plzen, Plzen, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Spacek","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohuslav","family":"Melichar","sequence":"additional","affiliation":[{"name":"Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz","family":"Kieszko","sequence":"additional","affiliation":[{"name":"Oncological Center of the Lublin Region, Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8423-479X","authenticated-orcid":false,"given":"Jitka","family":"Fucikova","sequence":"additional","affiliation":[{"name":"Department of Immunology, Charles University, Praha, Czech Republic"},{"name":"SOTIO a.s, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Hrnciarova","sequence":"additional","affiliation":[{"name":"First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic"},{"name":"SOTIO a.s, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9188-0327","authenticated-orcid":false,"given":"Roman Pawel","family":"Korolkiewicz","sequence":"additional","affiliation":[{"name":"SOTIO a.s, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Hraska","sequence":"additional","affiliation":[{"name":"SOTIO a.s, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jirina","family":"Bartunkova","sequence":"additional","affiliation":[{"name":"SOTIO a.s, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radek","family":"Spisek","sequence":"additional","affiliation":[{"name":"SOTIO a.s, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,1,6]]},"reference":[{"key":"2025100304332587000_10.1.e003190.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"2025100304332587000_10.1.e003190.2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt333"},{"key":"2025100304332587000_10.1.e003190.3","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat7807"},{"key":"2025100304332587000_10.1.e003190.4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2025100304332587000_10.1.e003190.5","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines8010025","article-title":"Development and optimization of a GMP-compliant manufacturing process for a personalized tumor lysate dendritic cell vaccine","volume":"8","author":"Boudousqui\u00e9","year":"2020","journal-title":"Vaccines"},{"key":"2025100304332587000_10.1.e003190.6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1185"},{"key":"2025100304332587000_10.1.e003190.7","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41573-020-0074-8","article-title":"Antitumour dendritic cell vaccination in a priming and boosting approach","volume":"19","author":"Harari","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"2025100304332587000_10.1.e003190.8","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.19.00508","article-title":"Immunotherapy in ovarian cancer: are we there yet?","volume":"37","author":"Kandalaft","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025100304332587000_10.1.e003190.9","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-019-02133-w","article-title":"A phase I\/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma","volume":"17","author":"Sarivalasis","year":"2019","journal-title":"J Transl Med"},{"key":"2025100304332587000_10.1.e003190.10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao5931"},{"key":"2025100304332587000_10.1.e003190.11","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28766"},{"key":"2025100304332587000_10.1.e003190.12","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-9-223"},{"key":"2025100304332587000_10.1.e003190.13","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"key":"2025100304332587000_10.1.e003190.14","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0787-6"},{"key":"2025100304332587000_10.1.e003190.15","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4145"},{"key":"2025100304332587000_10.1.e003190.16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00262-017-2068-x","article-title":"Phase I\/II trial of dendritic cell-based active cellular immunotherapy with DCVAC\/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer","volume":"67","author":"Fucikova","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"2025100304332587000_10.1.e003190.17","unstructured":"Podrazil M , Ro\u017ekov\u00e1 D , Hrom\u00e1dkov\u00e1 H . Ovarian cancer immunotherapy \u2013 clinical trial. poster presented at: 13th annual meeting of the Federation of clinical immunology societies. Boston, USA, 2013."},{"key":"2025100304332587000_10.1.e003190.18","unstructured":"Gynecologic Cancer InterGroup (GCIG) . CA 125 definitions agreed by GCIG November 2005. Available: https:\/\/gcigtrials.org\/system\/files\/CA%20125%20Definitions%20Agreed%20to%20by%20GCIG%20-%20November%202005.pdfhttps:\/\/doi.org\/ [Accessed 16 Mar 2021]."},{"key":"2025100304332587000_10.1.e003190.19","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2008.191"},{"key":"2025100304332587000_10.1.e003190.20","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3290","article-title":"Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer","volume":"3","author":"Goode","year":"2017","journal-title":"JAMA Oncol"},{"key":"2025100304332587000_10.1.e003190.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.09.039"},{"key":"2025100304332587000_10.1.e003190.22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0509182102"},{"key":"2025100304332587000_10.1.e003190.23","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100304332587000_10.1.e003190.24","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ccell.2020.11.009","article-title":"Immunomodulation by targeted anticancer agents","volume":"39","author":"Petroni","year":"2021","journal-title":"Cancer Cell"},{"key":"2025100304332587000_10.1.e003190.25","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2014.40"},{"key":"2025100304332587000_10.1.e003190.26","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jcyt.2013.11.013","article-title":"Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care","volume":"16","author":"Bapsy","year":"2014","journal-title":"Cytotherapy"},{"key":"2025100304332587000_10.1.e003190.27","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1081-8"},{"key":"2025100304332587000_10.1.e003190.28","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-149"},{"key":"2025100304332587000_10.1.e003190.29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1574"},{"key":"2025100304332587000_10.1.e003190.30","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1100-9"},{"key":"2025100304332587000_10.1.e003190.31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2189"},{"key":"2025100304332587000_10.1.e003190.32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1025"},{"key":"2025100304332587000_10.1.e003190.33","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00262-018-2257-2","article-title":"Phase I\/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer","volume":"68","author":"Zhang","year":"2019","journal-title":"Cancer Immunol Immunother"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-003190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:33:51Z","timestamp":1759491231000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-003190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,6]]},"published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1136\/jitc-2021-003190"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-003190","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}